Cargando…

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients

B cell-depleting therapies such as ocrelizumab (OCR) are highly effective in people with multiple sclerosis (MS). Especially at treatment start and initial infusion, infusion-related reactions (IRR) are a common adverse event. The relevance of acute changes of cell-depleting therapies on peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales: Akgün, Katja, Behrens, Johanna, Schriefer, Dirk, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696175/
https://www.ncbi.nlm.nih.gov/pubmed/36430240
http://dx.doi.org/10.3390/ijms232213759
_version_ 1784838242389983232
author Akgün, Katja
Behrens, Johanna
Schriefer, Dirk
Ziemssen, Tjalf
author_facet Akgün, Katja
Behrens, Johanna
Schriefer, Dirk
Ziemssen, Tjalf
author_sort Akgün, Katja
collection PubMed
description B cell-depleting therapies such as ocrelizumab (OCR) are highly effective in people with multiple sclerosis (MS). Especially at treatment start and initial infusion, infusion-related reactions (IRR) are a common adverse event. The relevance of acute changes of cell-depleting therapies on peripheral immune compartments and routine lab testing is important for clinical practice. We systematically analyzed routine blood parameters, detailed blood immunophenotyping and serum cytokine profiles in 45 MS patients starting on OCR. Blood samples were collected before and after corticosteroid premedication and directly after each OCR infusion of the first three ocrelizumab infusions. Blood B cells were rapidly depleted and accompanied only by a mild cytokine release at the first OCR infusion. Cytokine release was not significantly detectable from a third application in line with decreasing IRRs. B cell depletion was accompanied by short-lived changes in other immune cell populations in number, activation and cytokine secretion after each OCR infusion. Standard lab parameters did not show any clinically relevant changes. Our data demonstrate only mild changes during the first OCR infusion, which are not present any more during long-term treatment.
format Online
Article
Text
id pubmed-9696175
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96961752022-11-26 Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients Akgün, Katja Behrens, Johanna Schriefer, Dirk Ziemssen, Tjalf Int J Mol Sci Article B cell-depleting therapies such as ocrelizumab (OCR) are highly effective in people with multiple sclerosis (MS). Especially at treatment start and initial infusion, infusion-related reactions (IRR) are a common adverse event. The relevance of acute changes of cell-depleting therapies on peripheral immune compartments and routine lab testing is important for clinical practice. We systematically analyzed routine blood parameters, detailed blood immunophenotyping and serum cytokine profiles in 45 MS patients starting on OCR. Blood samples were collected before and after corticosteroid premedication and directly after each OCR infusion of the first three ocrelizumab infusions. Blood B cells were rapidly depleted and accompanied only by a mild cytokine release at the first OCR infusion. Cytokine release was not significantly detectable from a third application in line with decreasing IRRs. B cell depletion was accompanied by short-lived changes in other immune cell populations in number, activation and cytokine secretion after each OCR infusion. Standard lab parameters did not show any clinically relevant changes. Our data demonstrate only mild changes during the first OCR infusion, which are not present any more during long-term treatment. MDPI 2022-11-09 /pmc/articles/PMC9696175/ /pubmed/36430240 http://dx.doi.org/10.3390/ijms232213759 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Akgün, Katja
Behrens, Johanna
Schriefer, Dirk
Ziemssen, Tjalf
Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
title Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
title_full Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
title_fullStr Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
title_full_unstemmed Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
title_short Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
title_sort acute effects of ocrelizumab infusion in multiple sclerosis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696175/
https://www.ncbi.nlm.nih.gov/pubmed/36430240
http://dx.doi.org/10.3390/ijms232213759
work_keys_str_mv AT akgunkatja acuteeffectsofocrelizumabinfusioninmultiplesclerosispatients
AT behrensjohanna acuteeffectsofocrelizumabinfusioninmultiplesclerosispatients
AT schrieferdirk acuteeffectsofocrelizumabinfusioninmultiplesclerosispatients
AT ziemssentjalf acuteeffectsofocrelizumabinfusioninmultiplesclerosispatients